Quickfire Q&A delivers in-person insights from congress, bringing expert perspectives on the studies and data shaping clinical practice.
In this episode, recorded at the American Society of Clinical Oncology (ASCO) 2026 Annual Meeting, we speak to Roberto Leon-Ferre, breast medical oncologist, Mayo Clinic, Rochester, Minnesota, USA, about the latest developments in breast cancer and the growing potential to tailor treatment intensity to individual patients.
Key topics discussed include:
- KEYNOTE-522: How long-term findings are reinforcing the role of neoadjuvant immunotherapy in early-stage triple-negative breast cancer.
- OPTIMA: Could genomic assays help identify patients with extensive lymph node involvement who may not benefit from chemotherapy?
- Stage I triple-negative breast cancer: The emerging biomarkers that could support more personalized treatment and spare some patients unnecessary chemotherapy-related toxicities.
Read the latest issue of AMJ Oncology for more expert insights and highlights from ASCO 2026.
